Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
16 Luglio 2024 - 7:30AM
UK Regulatory
Nicox appoints experienced biotech leader Damian Marron as Chair of
the Board and Marc Le Bozec as Director
|
Press Release |
|
Nicox appoints experienced biotech leader Damian Marron as Chair of
the Board and Marc Le Bozec as Director |
- Damian
Marron is an experienced healthcare executive, non-executive
Director/Chair and advisor
- Marc Le
Bozec is an experienced life sciences entrepreneur
with a background in finance, organization and strategic
consulting
-
Jean-François Labbe retires as Chair and member of the
Board at the completion of his term; Les Kaplan has also decided to
step down from the Board
July 16th,
2024 – release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Growth Paris: FR0013018124,
ALCOX), an international ophthalmology company, today announced the
appointment of the highly experienced healthcare executive,
non-executive Director/Chair and advisor Damian Marron as Chair of
the Board of Directors. Marc Le Bozec, an experienced life sciences
entrepreneur, is also appointed as a new Director of Nicox. Both
Damian Marron and Marc Le Bozec are independent Directors in
accordance with the criteria set out by the recommendation 3 of the
Middlenext Governance Code.
Jean-François Labbe is retiring as Chair and member of the Board,
at the completion of his term. Les Kaplan has also decided to step
down from the Board. Both Jean-Francois Labbé and Les Kaplan have
contributed many years of service as Directors of Nicox.
“I am very pleased to welcome Damian Marron and Marc Le Bozec,
who both bring strong and relevant expertise in specific areas of
focus for Nicox at this stage of our development. In particular,
they will support exploring strategic options and financing
opportunities for the company alongside advising on business
development discussions on NCX 470 or our other drug
candidates.” said Gavin Spencer, Chief Executive
Officer of Nicox. “I would like to extend my thanks to
Jean-François Labbe and Les Kaplan for their long and dedicated
service to Nicox. We have appreciated their experience and guidance
as Board members and wish them all the best for the
future.”
“I am excited to join Nicox at this important stage in its
development. Based on its existing revenue plus a late-stage,
derisked asset, there are multiple strategic and business
development opportunities for the Company over the next 12-18
months. I am looking forward to working with Marc Le Bozec, Michele
Garufi and Gavin Spencer on the Board of Directors to support the
Company in my new role as Chair of the Board.” said
Damian Marron, Chair of the Board of Directors of
Nicox.
Damian Marron is a seasoned executive, 4-time CEO, Chair,
non-executive Board Member and company advisor with a proven track
record in value creation through public funding, venture capital,
portfolio planning, mergers and acquisitions, and license
agreements, as well as R&D collaborations. He has extensive
experience in both executive and independent administrator roles,
with a specialization in immuno-oncology, cellular therapy, and
orphan diseases. He is currently Chair of the Board of Directors
for Circio Holding ASA, Imophoron Ltd, and Indegra Therapeutics
Ltd.
Marc Le Bozec is a life sciences entrepreneur with a strong
background in finance, organization and strategic consulting. As
CFO of Cellectis, he led its IPO in Paris in 2007 and raised €120
million from 2006 to 2013. He then redirected the company Cytoo
towards human muscle research, leading to FDA validation and
becoming a key shareholder of the company. After nine years as a
professional investor, notably as fund manager at Financière
Arbevel, he resumed consulting and also founded Neurodyx in January
2024 to advance neuro-inflammation research.
At the date of this press release, Nicox's Board of Directors is
composed as follows:
- Damian Marron, Chair of the Board
and Independent Director,
- Gavin Spencer, Chief Executive
Officer and Director,
- Michele Garufi, Co-Founder and
Director,
- Marc le Bozec, Independent
Director.
|
|
About Nicox |
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470
(bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye
drop, for lowering intraocular pressure in patients with open-angle
glaucoma or ocular hypertension. Nicox generates revenue from
VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch +
Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in
multiple geographies, including to Harrow, Inc. in the U.S., and
Ocumension Therapeutics in the Chinese and in the majority of
Southeast Asian markets.
Nicox, headquartered in Sophia Antipolis, France, is listed on
Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC
Healthcare index.
For more information www.nicox.com |
|
Analyst coverage |
H.C. Wainwright & Co Yi Chen New York, U.S. |
|
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
|
Contacts |
|
Nicox
Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com |
Media / Investors
Sophie Baumont
Cohesion Bureau
+33 6 27 74 74 49 sophie.baumont@cohesionbureau.com |
|
Disclaimer |
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.
Risks factors which are likely to have a material effect on Nicox’s
business are presented in section 3 of the “Rapport Annuel
2023” which is available on Nicox’s website
(www.nicox.com).
Finally, this press release may be drafted in the French and
English languages. If both versions are interpreted differently,
the French language version shall prevail. |
Nicox S.A.
Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste
Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00 |
- EN_GovernanceJuly2024_PR_FINAL
Grafico Azioni Nicox (EU:ALCOX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Nicox (EU:ALCOX)
Storico
Da Nov 2023 a Nov 2024
